The study of markers of biological effect in cancer prevention research trials.
Biological markers may provide a valuable tool for the development of cancer prevention agents, for monitoring patient compliance to a selected intervention, or for further defining the carcinogenic process. This discussion focuses on markers of biological effect and the rationale for their use in cancer prevention trials. Recent studies with biological markers are investigating their incorporation into phase-I, -II, and -III chemoprevention clinical trial designs. Their use in clinical studies is expected to increase the number of agents that may be evaluated and to provide valuable information on the biological effectiveness of agents, doses, and schedules. Markers may also provide information to help in selecting high-risk groups for prevention research, and to indicate the pathways inhibited and the stage of carcinogenesis affected. Such information may prove of crucial importance in strengthening the rationale for long-term trials and other ancillary research. Biomarker research for colon carcinogenesis is discussed, including examples of a number of recent trials that may influence future progress in this area of prevention research. A crucial step in this process is marker validation as an aspect of major prospective observational and intervention studies where cancer incidence is the endpoint. We cannot be fully confident of markers as intermediate endpoints until the evidence from clinical trials is sufficiently strong to support major public health initiatives for prevention.
Greenwald
P
P
Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Witkin
K M
KM
Malone
W F
WF
Byar
D P
DP
Freedman
L S
LS
Stern
H R
HR
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002471:Cell Transformation, Neoplastic / Q000737:chemistry; D002986:Clinical Trials as Topic; D003106:Colon / Q000473:pathology; D003110:Colonic Neoplasms / Q000235:genetics; D004341:Drug Evaluation; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D009369:Neoplasms / Q000517:prevention & control*; D010349:Patient Compliance; D011230:Precancerous Conditions / Q000737:chemistry* / Q000473:pathology; D011379:Prognosis; D012106:Research; D012307:Risk Factors; D012680:Sensitivity and Specificity
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor